Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
In a phase I study, administration of an AAV2-FIX vector into the skeletal muscle of eight hemophilia B subjects proved safe and achieved local gene transfer and FIX expression for at least 10 months after vector injection, the last time point assessed by muscle biopsy. In hemophilia B dogs we have demonstrated FIX in both muscle biopsies and circulation >4 years following AAV2-FIX injection. Because circulating FIX levels remained less than 1% of normal in human subjects from the study, the duration of AAV2-mediated transgene expression in humans is unknown. We sought to determine if FIX gene transfer and expression persisted locally at injection sites. Muscle biopsies were obtained from one subject 3.7 years following treatment and revealed transgene FIX DNA and protein by quantitative PCR, DNA fluorescence in situ hybridization, and immunohistochemistry for FIX. These results demonstrate, for the first time, multiyear FIX expression by AAV2 vector in humans and suggest that improved muscle delivery provides effective treatment for protein deficiencies or muscle-specific diseases.
Jiang
Haiyan
H
Avigen, Inc., Alameda, CA 94502, USA.
Pierce
Glenn F
GF
Ozelo
Margareth C
MC
de Paula
Erich V
EV
Vargas
Joseph A
JA
Smith
Peter
P
Sommer
Jürg
J
Luk
Alvin
A
Manno
Catherine S
CS
High
Katherine A
KA
Arruda
Valder R
VR
D004247:DNA / Q000032:analysis; D000229:Dependovirus / Q000235:genetics; D005164:Factor IX / Q000032:analysis / Q000235:genetics*; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D002836:Hemophilia B / Q000628:therapy*; D006801:Humans; D018482:Muscle, Skeletal / Q000737:chemistry / Q000378:metabolism*; D019076:Transgenes / Q000235:genetics; D016896:Treatment Outcome
D005164:Factor IX; D004247:DNA